Intravenous sulprostone infusion in the treatment of retained placenta
- PMID: 22862433
- DOI: 10.1111/j.1600-0412.2012.01506.x
Intravenous sulprostone infusion in the treatment of retained placenta
Abstract
Objective: To analyze the effectiveness of intravenous sulprostone infusion for the treatment of retained placenta without massive primary hemorrhage among women at an university hospital over a three-year period.
Design: Retrospective observational study.
Setting: University teaching hospital.
Population: 126 consecutive women with placental retention and intravenous sulprostone infusion as primary treatment performed from October 2007 up to December 2011.
Methods: Hospital records of women who received sulprostone infusion to attempt placental expulsion were reviewed.
Main outcome measures: Primary endpoints of the study were expulsion of placenta and the total amount of blood loss during delivery.
Results: The placenta was successfully expelled in 39.7% of cases, whereas 60.3% of women underwent manual removal of placenta. Blood loss was significantly lower in women with successful placental expulsion than in women who had manual removal of the placenta (582 ± 431 ml vs. 1275 ± 721 ml, p < 0.0001). Sulprostone infusion did not cause adverse effects or significant postpartum morbidity.
Conclusions: Intravenous sulprostone infusion is safe and reduces both blood loss and the need for manual removal of the placenta.
© 2012 The Authors Acta Obstetricia et Gynecologica Scandinavica © 2012 Nordic Federation of Societies of Obstetrics and Gynecology.
Similar articles
-
Sulprostone reduces the need for the manual removal of the placenta in patients with retained placenta: a randomized controlled trial.Am J Obstet Gynecol. 2006 Feb;194(2):446-50. doi: 10.1016/j.ajog.2005.08.029. Am J Obstet Gynecol. 2006. PMID: 16458644 Clinical Trial.
-
No reduction of manual removal after misoprostol for retained placenta: a double-blind, randomized trial.Acta Obstet Gynecol Scand. 2013 Apr;92(4):398-403. doi: 10.1111/aogs.12065. Epub 2013 Jan 21. Acta Obstet Gynecol Scand. 2013. PMID: 23231499 Clinical Trial.
-
Sulprostone reduces the need for manual removal of the placenta in patients with retained placenta: a randomized controlled trial.Am J Obstet Gynecol. 2007 Mar;196(3):e13; author reply e13-4. doi: 10.1016/j.ajog.2006.09.045. Am J Obstet Gynecol. 2007. PMID: 17346503 No abstract available.
-
The Salford Third Stage Trial. Oxytocin plus ergometrine versus oxytocin alone in the active management of the third stage of labor.Online J Curr Clin Trials. 1993 Aug 13;Doc No 83:[2305 words; 32 paragraphs]. Online J Curr Clin Trials. 1993. PMID: 8306013 Review.
-
[RU 486 and sulprostone in pregnancy termination in the 2nd and 3rd trimesters].J Gynecol Obstet Biol Reprod (Paris). 1994;23(6):701-5. J Gynecol Obstet Biol Reprod (Paris). 1994. PMID: 7995916 Review. French.
Cited by
-
Prostaglandins for management of retained placenta.Cochrane Database Syst Rev. 2014 May 16;2014(5):CD010312. doi: 10.1002/14651858.CD010312.pub2. Cochrane Database Syst Rev. 2014. PMID: 24833288 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources